Stanford University
Showing 29,481-29,500 of 36,305 Results
-
Richelle Smith
Postdoctoral Scholar, Electrical Engineering
BioRichelle L. Smith is a Postdoctoral Scholar at Stanford University with Professor Tom Lee. She received the B.S. and M.S. degrees in Electrical Engineering-Electrophysics from the University of Southern California (USC) in 2017, and the M.S. and Ph.D. degrees in Electrical Engineering from Stanford University in 2019 and 2024, respectively.
Her research interests include analog/mixed-signal circuit design and energy-efficient systems, with a focus on phase-domain communications and computing. Recent projects encompass oscillatory computing for combinatorial optimization, quantum computing emulation with oscillator circuits, brain-inspired/neuromorphic circuit design, as well as wireline transceivers and phase-domain/edge modulation signaling.
She has acted as a technical consultant to Rambus Labs. She has held internship positions at Linear Technology, Rambus Labs, Stanford Brains in Silicon Lab, TDK-InvenSense, and Silicon Laboratories. She holds 5 U.S. patents. Dr. Smith serves as a Reviewer for IEEE Transactions on Circuits and Systems—Part I: Regular Papers, IEEE Transactions on Circuits and Systems—Part II: Express Briefs, and IEEE Journal on Emerging and Selected Topics in Circuits and Systems.
Selected Awards:
• SPOTLIGHT paper, IEEE Journal on Emerging and Selected Topics in Circuits and Systems (JETCAS), 2024
• IEEE Solid-State Circuits Society (SSCS) Predoctoral Achievement Award, 2022–2023
• ARCS Foundation Northern California Fellowship (William K. Bowes, Jr. Foundation Scholar), 2022–2024
• Cadence Women in Technology Scholarship, 2021
• Analog Devices Outstanding Student Designer Award, 2019
• Stanford Graduate Fellowship (Sang Samuel Wang Scholar), 2017–2022
• NSF Graduate Research Fellowship, 2017–2022
• USC Discovery Scholar Prize, 2017
• Astronaut Scholarship, 2016
• Barry Goldwater Scholarship, 2016
• Tau Beta Pi Forge No. 42 Scholarship, 2015
• Rambus Innovator of the Future Scholarship, 2013
• USC Trustee Full Tuition Scholarship, 2013–2017 -
Stephanie Melissa Smith
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsI am involved with clinical research related to cancer survivorship, with a particular focus on late effects of childhood cancer treatments and community partnerships to improve health equity for adolescent/young adult cancer survivors in under-resourced settings.
-
Stephanie Mariko Wilcox, FNP-C, RN, MSN
Affiliate, IT Services
BioStephanie Wilcox, FNP-C is a nurse practitioner at the Cancer Center, South Bay. She graduated with her Family Nurse Practitioner (FNP) certificate from the University of California, San Francisco (UCSF) and her master of science in nursing (MSN) at the University of San Francisco (USF). She also has a bachelor's of science (BS) degree in Molecular Biology and Art History from the University of California, San Diego (UCSD). Her area of clinical practice is in medical oncology.
-
Stephen J Smith
Professor of Molecular and Cellular Physiology, Emeritus
Current Research and Scholarly InterestsStephen Smith remains active in the computational microscopy field and is also currently using data science tools to explore new transcriptomic perspectives on signaling by neuropeptides and other neuromodulators in brains of diverse animal species. These exploration have unearthed evidence for a previous unrecognized ubiquity of local neuropeptide signaling and possible critical involvement of such signaling in memory engram formation.
-
Stephen Smith, MD
Clinical Assistant Professor, Ophthalmology
Current Research and Scholarly InterestsRESEARCH OVERVIEW
Dr. Smith’s primary professional interest is developing solutions for unmet clinical and surgical vitreoretinal needs. Beginning in medical school, one of his primary focuses has been improving treatment outcomes in patients with retinoblastoma (RB). During his second year in medical school Dr. Smith published a manuscript on a novel technique to reduce the risk of tumor spread following intravitreal drug delivery in patients with RB. His work summarizing published data on tumor spread following intravitreal injection therapy (IVT) for RB has resulted in multiple platform presentations at national and international meetings, including an invited lecture at ARVO 2014. The results of this study influenced the growing trend toward broader acceptance of intravitreal chemotherapy in pediatric patients with treatment-resistant retinoblastoma vitreous seeds. A primary active area of research has included studying and publishing on ocular toxicity that results from the use of intravitreal melphalan and other agents for RB. This work, and subsequent publications from leaders in the field, has led to an increased awareness of ocular toxicity caused by injecting chemotherapeutic agents into the eyes of young children. This highlighted the need for toxicity data on additional chemotherapeutic agents for local delivery. To answer this question, Dr. Smith assembled an excellent group of collaborators and consultants, including internationally known experts at Bascom Palmer, Mayo Clinic, and Emory University. As a resident he secured a highly competitive career starter grant from the Knights Templar Foundation and used that funding and the expertise of his collaborators to carry out preclinical ocular toxicity studies of combination intravitreal chemotherapy for RB. His work in RB has led to a broader recognition of the challenges facing patients with RB who receive IVT and has led to a continued search for optimal local injectable therapies for patients with this disease.
INNOVATION HIGHLIGHTS
In addition to his work in retinoblastoma, Dr. Smith has been actively involved in developing technologies to improve outcomes for patients receiving intravitreal injection therapy (IVT) for macular degeneration, diabetic retinopathy, retinal vein occlusions and more. IVT has become the most common procedure performed by retina specialists in the United States, with an estimated 6 million injections given in the United States alone in 2016. Dr. Smith has co-developed technology that simplifies and streamlines the IVT process, removing barriers to treatment and improving patient outcomes. His work in innovation covers pre-clinical and clinical development work, and has given him expertise in diverse subject areas including fundraising, intellectual property portfolio development, team building, and business administration. He is a co-founder of iRenix Medical, a biotechnology and medical device start-up company committed to improving vision through optimization of the IVT process.
Dr. Smith remains dedicated to helping improve and restore vision and quality of life in patients with vitreoretinal disease. He is currently involved in both medical device and pharmaceutical innovation, and serves as a mentor for the Stanford University Biodesign Innovation Course.
